NOVATO, Calif., Aug. 29, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that PROCYSBI (cysteamine bitartrate) will be featured in an upcoming presentation at the 16 th Congress of the International Pediatric Nephrology Association being held in Shanghai, China. The presentation, titled "Extended treatment of patients with cystinosis and CKD with RP103 demonstrates efficacy and safety," will be given by Dr. Craig Langman of the Northwestern University Feinberg School of Medicine and is scheduled for 5:15 p.m. China Standard Time on Sunday, September 1, 2013 (Abstract O-42). Additional information about the conference can be found at www.ipna2013.org. About Raptor Pharmaceutical Raptor Pharmaceutical Corp. is a biopharmaceutical company focused on developing and commercializing life-altering therapeutics that treat rare, debilitating and often fatal diseases. The company's first product, PROCYSBI (cysteamine bitartrate) delayed-release capsules, has been approved by the FDA, and recommended for marketing authorization by the European Committee for Medicinal Products for Human Use (CHMP) for the management of nephropathic cystinosis, a rare metabolic lysosomal storage disease. Raptor's pipeline also includes RP103 in a Phase 2/3 trial for Huntington's disease and a Phase 2 trial in nonalcoholic fatty liver disease in children. PROCYSBI has orphan designation for nephropathic cystinosis in the U.S., recommended orphan designation in the EU and RP103 has received U.S. orphan drug designation for Huntington's disease. For additional information, please visit www.raptorpharma.com. About PROCYSBI (cysteamine bitartrate) delayed-release capsules PROCYSBI is a cystine depleting agent that is approved in the U.S. for the management of nephropathic cystinosis in adults and children ages 6 years and older. It is contraindicated in patients with a hypersensitivity to penicillamine. The most commonly reported side effects are vomiting, abdominal pain/discomfort, headaches, nausea, diarrhea, anorexia/decreased appetite, breath odor, fatigue, dizziness, skin odor and rash. For additional information on PROCYSBI, including full prescribing information, please visit www.procysbi.com.
CONTACT: Georgia Erbez Chief Financial Officer Raptor Pharmaceutical Corp. (415) 408-6231 email@example.com INVESTOR CONTACTS: Westwicke Partners, LLC Stefan Loren, Ph.D. Managing Director (443) 213-0507 firstname.lastname@example.org Robert H. Uhl Managing Director (858) 356-5932 email@example.com MEDIA CONTACT: Carolyn Hawley Canale Communications (619) 849-5375 firstname.lastname@example.org